"#",Jurisdiction,Kind,Display Key,Lens ID,Publication Date,Publication Year,Application Number,Application Date,Priority Numbers,Earliest Priority Date,Title,Abstract,Applicants,Inventors,Owners,URL,Document Type,Has Full Text,Cites Patent Count,Cited by Patent Count,Simple Family Size,Extended Family Size,Sequence Count,CPC Classifications,IPCR Classifications,US Classifications,NPL Citation Count,NPL Resolved Citation Count,NPL Resolved Lens ID(s),NPL Resolved External ID(s),NPL Citations,Legal Status
1,US,A1,US 2007/0038292 A1,072-566-797-189-618,2007-02-15,2007,US 20076305 A,2005-08-09,US 20076305 A,2005-08-09,Bio-absorbable stent,"The present invention is a novel implantable medical device comprised of a tubular double lumen, radially compressible, axially flexible and expandable, bio-absorbable “bladder”-type stent.",DANIELPOUR MOISE,DANIELPOUR MOISE,CEDARS-SINAI MEDICAL CENTER (2008-02-20),https://lens.org/072-566-797-189-618,Patent Application,yes,22,57,4,4,0,A61F2/82;;A61F2/94;;A61F2250/0003;;A61F2230/0091;;A61F2/94;;A61F2/82;;A61F2250/0003;;A61F2230/0091,A61F2/82;;A61F2/94,623/1.42;;623/23.67;;623/1.39,0,0,,,,DISCONTINUED
2,WO,A3,WO 2007/021593 A3,020-551-347-510-330,2008-01-03,2008,US 2006/0030492 W,2006-08-03,US 20076305 A,2005-08-09,BIO-ABSORBABLE STENT,"The present invention is a novel implantable medical device comprised of a tubular double lumen, radially compressible, axially flexible and expandable, bio-absorbable ""bladder""-type stent.",CEDARS SINAI MEDICAL CENTER;;DANIELPOUR MOISE,DANIELPOUR MOISE,,https://lens.org/020-551-347-510-330,Search Report,yes,3,0,4,4,0,A61F2/82;;A61F2/94;;A61F2250/0003;;A61F2230/0091;;A61F2/94;;A61F2/82;;A61F2250/0003;;A61F2230/0091,A61F2/82;;A61F2/94,,0,0,,,,PENDING
3,EP,A2,EP 1912599 A2,065-345-824-016-489,2008-04-23,2008,EP 06789419 A,2006-08-03,US 2006/0030492 W;;US 20076305 A,2005-08-09,BIO-ABSORBABLE STENT,,CEDARS SINAI MEDICAL CENTER,DANIELPOUR MOISE,,https://lens.org/065-345-824-016-489,Patent Application,yes,0,0,4,4,0,A61F2/82;;A61F2/94;;A61F2250/0003;;A61F2230/0091;;A61F2/94;;A61F2/82;;A61F2250/0003;;A61F2230/0091,A61F2/82;;A61F2/94,,0,0,,,,DISCONTINUED
4,WO,A2,WO 2007/021593 A2,096-198-885-160-772,2007-02-22,2007,US 2006/0030492 W,2006-08-03,US 20076305 A,2005-08-09,BIO-ABSORBABLE STENT,"The present invention is a novel implantable medical device comprised of a tubular double lumen, radially compressible, axially flexible and expandable, bio-absorbable ""bladder""-type stent.",CEDARS SINAI MEDICAL CENTER;;DANIELPOUR MOISE,DANIELPOUR MOISE,,https://lens.org/096-198-885-160-772,Patent Application,yes,0,2,4,4,0,A61F2/82;;A61F2/94;;A61F2250/0003;;A61F2230/0091;;A61F2/94;;A61F2/82;;A61F2250/0003;;A61F2230/0091,A61F2/82;;A61F2/94,,0,0,,,,PENDING
5,US,B2,US 10612022 B2,195-752-608-024-312,2020-04-07,2020,US 201615575721 A,2016-05-20,US 201615575721 A;;US 201562164475 P;;US 2016/0033630 W,2015-05-20,ETS factors regulate neural stem cell depletion and gliogenesis in Ras pathway glioma,"Described herein are composition and methods related to targeting the Nf1-Ras-Ets axis, that when perturbed, is identified as playing a role in initiation and maintenance in glioma. A postnatal, mosaic, autochthonous, glioma model that captures the first hours and days of gliomagenesis in more resolution than conventional genetically engineered mouse models of cancer demonstrates that disruption of the Nf1-Ras pathway in the ventricular zone at multiple signaling nodes uniformly results in rapid neural stem cell depletion, progenitor hyperproliferation, and gliogenic lineage restriction. By abolishing Ets subfamily activity, which is upregulated downstream of Ras, there is block of glioma initiation, thereby providing new therapeutic avenues for targeting glioma.",CEDARS SINAI MEDICAL CENTER,BREUNIG JOSHUA;;DANIELPOUR MOISE,CEDARS-SINAI MEDICAL CENTER (2016-05-23),https://lens.org/195-752-608-024-312,Granted Patent,yes,2,0,4,4,2,A61K38/1709;;A61P35/00;;A61P35/00;;C12N15/113;;C12N15/113;;C12N2310/14;;C12N2310/14;;C12N2310/531;;C12N2310/531;;G01N33/5011;;G01N33/5058,G01N33/50;;A61K38/17;;A61P35/00;;C12N15/113,,7,5,090-604-998-477-103;;014-729-260-462-557;;022-906-467-976-568;;090-604-998-477-103;;041-443-639-960-580,26146073;;10.1016/j.celrep.2015.06.012;;10.1016/j.brainres.2012.11.044;;23261661;;pmc3179115;;10.1073/pnas.1019012108;;21896734;;26146073;;10.1016/j.celrep.2015.06.012;;22207524;;10.1007/s00432-011-1114-x,"Breunig et al. Cell Reports. 2015 vol. 12:258-271.;;International Search Report and Written Opinion for PCT/US2016/033630 dated Oct. 19, 2016, 10 pages.;;Arcella et al., Rapamycin Inhibits the Growth of Glioblastoma, Brain Research, 2013, vol. 1495, pp. 37-51.;;Banerjee et al., Neurofibromatosis-1 Regulates mTOR-Mediated Astrocyte Growth and Glioma Formation in a TSC/Rheb-Independent Manner, Proc. Nat. Acad. Sci., 2011, vol. 108(38), pp. 15966-16001.;;Blum et al., Ras Inhibition in Glioblastoma Down-regulates Hypoxia-Inducible Factor-1α, Causing Glycolysis Shutdown and Cell Death, Cancer Res., 2005, vol. 65(3), pp. 999-1006.;;Breunig et al., Ets Factors Regulate Neural Stem Cell Depletion and Gliogenesis in Ras Pathway Glioma, Cell Rep. ePub., 2015, vol. 12(2), pp. 258-271.;;Wang et al., MiR-181d Acts as a Tumor Suppressor in Glioma by Targeting K-ras and Bcl-2., J. Cancer Res. Clin. Oncol, 2012, vol. 138, pp. 573-584.",ACTIVE
6,WO,A9,WO 2016/187586 A9,045-556-979-342-259,2017-05-18,2017,US 2016/0033630 W,2016-05-20,US 201562164475 P,2015-05-20,ETS FACTORS REGULATE NEURAL STEM CELL DEPLETION AND GLIOGENESIS IN RAS PATHWAY GLIOMA,"Described herein are composition and methods related to targeting the Nf1-Ras-Ets axis, that when perturbed, is identified as playing a role in initiation and maintenance in glioma. A postnatal, mosaic, autochthonous, glioma model that captures the first hours and days of gliomagenesis in more resolution than conventional genetically engineered mouse models of cancer demonstrates that disruption of the Nf1-Ras pathway in the ventricular zone at multiple signaling nodes uniformly results in rapid neural stem cell depletion, progenitor hyperproliferation, and gliogenic lineage restriction. By abolishing Ets subfamily activity, which is upregulated downstream of Ras, there is block of glioma initiation, thereby providing new therapeutic avenues for targeting glioma.",CEDARS SINAI MEDICAL CENTER,BREUNIG JOSHUA;;DANIELPOUR MOISE,,https://lens.org/045-556-979-342-259,Search Report,yes,0,0,4,4,0,G01N33/5011;;G01N33/5058;;A61K38/1709;;C12N2310/14;;C12N2310/531;;C12N15/113;;A61P35/00;;C12N2310/14;;C12N2310/531;;C12N15/113;;A61P35/00,A61P33/00;;A61K38/00;;C12N15/113;;G01N33/68,,0,0,,,,PENDING
7,WO,A1,WO 2016/187586 A1,182-669-685-151-017,2016-11-24,2016,US 2016/0033630 W,2016-05-20,US 201562164475 P,2015-05-20,ETS FACTORS REGULATE NEURAL STEM CELL DEPLETION AND GLIOGENESIS IN RAS PATHWAY GLIOMA,"Described herein are composition and methods related to targeting the Nf1-Ras-Ets axis, that when perturbed, is identified as playing a role in initiation and maintenance in glioma. A postnatal, mosaic, autochthonous, glioma model that captures the first hours and days of gliomagenesis in more resolution than conventional genetically engineered mouse models of cancer demonstrates that disruption of the Nf1-Ras pathway in the ventricular zone at multiple signaling nodes uniformly results in rapid neural stem cell depletion, progenitor hyperproliferation, and gliogenic lineage restriction. By abolishing Ets subfamily activity, which is upregulated downstream of Ras, there is block of glioma initiation, thereby providing new therapeutic avenues for targeting glioma.",CEDARS SINAI MEDICAL CENTER,BREUNIG JOSHUA;;DANIELPOUR MOISE,,https://lens.org/182-669-685-151-017,Patent Application,yes,1,1,4,4,0,G01N33/5011;;G01N33/5058;;A61K38/1709;;C12N2310/14;;C12N2310/531;;C12N15/113;;A61P35/00;;C12N2310/14;;C12N2310/531;;C12N15/113;;A61P35/00,A61P33/00;;A61K38/00;;C12N15/113;;G01N33/68,,3,3,041-443-639-960-580;;022-906-467-976-568;;090-604-998-477-103,22207524;;10.1007/s00432-011-1114-x;;pmc3179115;;10.1073/pnas.1019012108;;21896734;;26146073;;10.1016/j.celrep.2015.06.012,"WANG ET AL.: ""MiR-181d acts as a tumor suppressor in glioma by targeting K-ras and Bcl-2."", J CANCER RES CLIN ONCOL, vol. 138, no. 4, April 2012 (2012-04-01), pages 573 - 584, XP035030089;;BANERJEE ET AL.: ""Neurofibromatosis-1 regulates mTOR-mediated astrocyte growth and glioma formation in a TSC/Rheb-independent manner."", PROC NAT ACAD SCI, vol. 108, no. 38, 20 September 2011 (2011-09-20), pages 15966 - 16001, XP055331566;;BREUNIG ET AL.: ""Ets Factors Regulate Neural Stem Cell Depletion and Gliogenesis in Ras Pathway Glioma."", CELL REP, vol. 12, no. 2, 2 July 2015 (2015-07-02), pages 258 - 271, XP055331567",PENDING
8,US,A1,US 2018/0291375 A1,059-868-081-286-239,2018-10-11,2018,US 201615575721 A,2016-05-20,US 201615575721 A;;US 201562164475 P;;US 2016/0033630 W,2015-05-20,ETS FACTORS REGULATE NEURAL STEM CELL DEPLETION AND GLIOGENESIS IN RAS PATHWAY GLIOMA,"Described herein are composition and methods related to targeting the Nf1-Ras-Ets axis, that when perturbed, is identified as playing a role in initiation and maintenance in glioma. A postnatal, mosaic, autochthonous, glioma model that captures the first hours and days of gliomagenesis in more resolution than conventional genetically engineered mouse models of cancer demonstrates that disruption of the Nf1-Ras pathway in the ventricular zone at multiple signaling nodes uniformly results in rapid neural stem cell depletion, progenitor hyperproliferation, and gliogenic lineage restriction. By abolishing Ets subfamily activity, which is upregulated downstream of Ras, there is block of glioma initiation, thereby providing new therapeutic avenues for targeting glioma.",CEDARS SINAI MEDICAL CENTER,BREUNIG JOSHUA;;DANIELPOUR MOISE,CEDARS-SINAI MEDICAL CENTER (2016-05-23),https://lens.org/059-868-081-286-239,Patent Application,yes,0,0,4,4,0,A61K38/1709;;A61P35/00;;A61P35/00;;C12N15/113;;C12N15/113;;C12N2310/14;;C12N2310/14;;C12N2310/531;;C12N2310/531;;G01N33/5011;;G01N33/5058,C12N15/113;;A61P35/00,,1,1,090-604-998-477-103,26146073;;10.1016/j.celrep.2015.06.012,Breunig et al. Cell Reports. 2015 Vol. 12:258-271,ACTIVE
9,CA,A1,CA 3176713 A1,172-664-596-052-652,2021-06-17,2021,CA 3176713 A,2020-12-09,US 201962945713 P;;US 2020/0063979 W,2019-12-09,USE OF FGFR INHIBITORS FOR TREATMENT OF IDIOPATHIC SHORT STATURE,The present invention describes methods for treating idiopathic short stature. Described herein are also methods of increasing a subject's height. The methods involve administering an effective amount of a pan FGFR inhibitor or a selective FGFR inhibitor to the subject. An example of an FGRF inhibitor used in the methods described herein is erdafitinib.,CEDARS SINAI MEDICAL CENTER;;HWA VIVIAN,DANIELPOUR MOISE;;MAJLESSIPOUR FATANEH;;HWA VIVIAN,,https://lens.org/172-664-596-052-652,Patent Application,no,0,0,3,3,0,A61K31/498;;A61K47/54;;A61P43/00;;A61K31/498,A61K39/395;;A61K47/54;;C07C275/16,,0,0,,,,PENDING
10,WO,A1,WO 2021/119108 A1,007-505-821-028-480,2021-06-17,2021,US 2020/0063979 W,2020-12-09,US 201962945713 P,2019-12-09,USE OF FGFR INHIBITORS FOR TREATMENT OF IDIOPATHIC SHORT STATURE,The present invention describes methods for treating idiopathic short stature. Described herein are also methods of increasing a subject's height. The methods involve administering an effective amount of a pan FGFR inhibitor or a selective FGFR inhibitor to the subject. An example of an FGRF inhibitor used in the methods described herein is erdafitinib.,CEDARS SINAI MEDICAL CENTER;;HWA VIVIAN,HWA VIVIAN;;DANIELPOUR MOISE;;MAJLESSIPOUR FATANEH,,https://lens.org/007-505-821-028-480,Patent Application,yes,5,0,3,3,0,A61K31/498;;A61K47/54;;A61P43/00;;A61K31/498,A61K39/395;;A61K47/54;;C07C275/16,,2,2,003-785-531-492-035;;102-525-300-058-707,10.1002/jbmr.1810;;23129509;;31371388;;pmc6719459;;10.1083/jcb.201906059,"WOHRLE ET AL.: ""Pharmacological Inhibition of Fibroblast Growth Factor (FGF) Receptor Signaling Ameliorates FGF23-Mediated Hypophosphatemic Rickets"", J BONE MINER RES, vol. 28, no. 4, April 2013 (2013-04-01), pages 899 - 911, XP055072850, DOI: 10.1002/jbmr.1810;;SAW SANJAY, AIKEN ALISON, FANG HUI, MCKEE TREVOR D., BREGANT SARAH, SANCHEZ OTTO, CHEN YAN, WEISS ASHLEY, DICKSON BRENDAN C., CZAR: ""Metalloprotease inhibitor TIMP proteins control FGF-2 bioavailability and regulate skeletal growth"", J CELL BIOL, vol. 218, no. 9, August 2019 (2019-08-01), pages 3134 - 3152, XP055836877",PENDING
11,US,A1,US 2023/0011935 A1,177-758-324-088-917,2023-01-12,2023,US 202017782534 A,2020-12-09,US 202017782534 A;;US 201962945713 P;;US 2020/0063979 W,2019-12-09,USE OF FGFR INHIBITORS FOR TREATMENT OF IDIOPATHIC SHORT STATURE,The present invention describes methods for treating idiopathic short stature. Described herein are also methods of increasing a subject’s height. The methods involve administering an effective amount of a pan FGFR inhibitor or a selective FGFR inhibitor to the subject. An example of an FGRF inhibitor used in the methods described herein is erdafitinib.,CEDARS SINAI MEDICAL CENTER;;CHILDREN’S HOSPITAL MEDICAL CENTER,DANIELPOUR MOISE;;MAJLESSIPOUR FATANEH;;HWA VIVIAN,CHILDREN'S HOSPITAL MEDICAL CENTER (2022-09-16);;CEDARS-SINAI MEDICAL CENTER (2021-02-08),https://lens.org/177-758-324-088-917,Patent Application,yes,0,0,3,3,0,A61K31/498;;A61K47/54;;A61P43/00;;A61K31/498,A61K31/498;;A61K47/54;;A61P43/00,,0,0,,,,PENDING
12,AU,A1,AU 2016/389495 A1,004-888-910-424-102,2018-08-16,2018,AU 2016/389495 A,2016-12-30,US 201662287197 P;;US 2016/0069442 W,2016-01-26,Systems and methods for in vivo dual recombinase-mediated cassette exchange (dRMCE) and disease models thereof,Described herein are donor vectors and systems for use in,CEDARS SINAI MEDICAL CENTER,BREUNIG JOSHUA;;DANIELPOUR MOISE;;KIM GI BUM,,https://lens.org/004-888-910-424-102,Patent Application,no,0,1,13,13,0,A01K67/0275;;C12N15/8509;;A01K2217/07;;A01K2227/105;;A01K2267/0331;;A01K67/0275;;C12N15/8509;;A01K2267/0331;;A01K2217/07;;A01K2227/105;;C12N2015/8527;;C12N2015/8572;;C12N2800/30;;C12N2310/20;;A01K67/0275;;A01K2217/07;;A01K2227/105;;A01K2267/0331;;A61K48/0066;;A61K49/0008;;C12N9/22;;C12N15/11;;C12N15/8509;;C12N2015/8572;;C12N2800/80;;C12N2830/50,C12N15/85,,0,0,,,,ACTIVE
13,CA,A1,CA 3012042 A1,042-518-170-891-679,2017-08-03,2017,CA 3012042 A,2016-12-30,US 201662287197 P;;US 2016/0069442 W,2016-01-26,SYSTEMS AND METHODS FOR IN VIVO DUAL RECOMBINASE-MEDIATED CASSETTE EXCHANGE (DRMCE) AND DISEASE MODELS THEREOF,"Described herein are donor vectors and systems for use in in vivo dual recombinase-mediated cassette exchange. Also described are animal models for consistent, rigorous, and facile investigation of transgene expression. Further described are methods of screening for therapeutic drugs using these animal models, and methods of treatment",CEDARS SINAI MEDICAL CENTER,BREUNIG JOSHUA;;DANIELPOUR MOISE;;KIM GI BUM,,https://lens.org/042-518-170-891-679,Patent Application,no,0,1,13,13,20,A01K67/0275;;C12N15/8509;;A01K2217/07;;A01K2227/105;;A01K2267/0331;;A01K67/0275;;C12N15/8509;;A01K2267/0331;;A01K2217/07;;A01K2227/105;;C12N2015/8527;;C12N2015/8572;;C12N2800/30;;C12N2310/20;;A01K67/0275;;A01K2217/07;;A01K2227/105;;A01K2267/0331;;A61K48/0066;;A61K49/0008;;C12N9/22;;C12N15/11;;C12N15/8509;;C12N2015/8572;;C12N2800/80;;C12N2830/50,C12N15/85,,0,0,,,,PENDING
14,KR,A,KR 20180101535 A,127-091-939-599-709,2018-09-12,2018,KR 20187023347 A,2016-12-30,US 201662287197 P;;US 2016/0069442 W,2016-01-26,생체내 이중 재조합효소-매개된 카세트 교환 (dRMCE)을 위한 시스템과 방법 및 이들의 질환 모형,"생체내 이중 재조합효소-매개된 카세트 교환에서 이용을 위한 공여자 벡터 및 시스템이 본원에서 설명된다. 도입유전자 발현의 일관되고, 엄격하고, 손쉬운 조사를 위한 동물 모형이 또한 설명된다. 이들 동물 모형을 이용하여 치료적 약물을 선별검사하는 방법, 그리고 치료 방법이 더욱 설명된다.",CEDARS SINAI MEDICAL CENTER,BREUNIG JOSHUA;;DANIELPOUR MOISE;;KIM GI BUM,,https://lens.org/127-091-939-599-709,Patent Application,no,0,1,13,13,40,A01K67/0275;;C12N15/8509;;A01K2217/07;;A01K2227/105;;A01K2267/0331;;A01K67/0275;;C12N15/8509;;A01K2267/0331;;A01K2217/07;;A01K2227/105;;C12N2015/8527;;C12N2015/8572;;C12N2800/30;;C12N2310/20;;A01K67/0275;;A01K2217/07;;A01K2227/105;;A01K2267/0331;;A61K48/0066;;A61K49/0008;;C12N9/22;;C12N15/11;;C12N15/8509;;C12N2015/8572;;C12N2800/80;;C12N2830/50,C12N15/85;;A01K67/027,,0,0,,,,DISCONTINUED
15,US,A1,US 2023/0084201 A1,057-833-798-192-608,2023-03-16,2023,US 202217930558 A,2022-09-08,US 202217930558 A;;US 201816071407 A;;US 2016/0069442 W;;US 201662287197 P,2016-01-26,SYSTEMS AND METHODS FOR IN VIVO DUAL RECOMBINASE-MEDIATED CASSETTE EXCHANGE (dRMCE) AND DISEASE MODELS THEREOF,"Described herein are donor vectors and systems for use in in vivo dual recombinase-mediated cassette exchange. Also described are animal models for consistent, rigorous, and facile investigation of transgene expression. Further described are methods of screening for therapeutic drugs using these animal models, and methods of treatment.",CEDARS SINAI MEDICAL CENTER,BREUNIG JOSHUA;;DANIELPOUR MOISE;;KIM GI BUM,CEDARS-SINAI MEDICAL CENTER (2017-01-10),https://lens.org/057-833-798-192-608,Patent Application,yes,0,0,13,13,0,A01K67/0275;;C12N15/8509;;A01K2217/07;;A01K2227/105;;A01K2267/0331;;A01K67/0275;;C12N15/8509;;A01K2267/0331;;A01K2217/07;;A01K2227/105;;C12N2015/8527;;C12N2015/8572;;C12N2800/30;;C12N2310/20;;A01K67/0275;;A01K2217/07;;A01K2227/105;;A01K2267/0331;;A61K48/0066;;A61K49/0008;;C12N9/22;;C12N15/11;;C12N15/8509;;C12N2015/8572;;C12N2800/80;;C12N2830/50,A01K67/027;;C12N15/85;;A61K48/00;;A61K49/00;;C12N9/22;;C12N15/11,,0,0,,,,PENDING
16,US,A1,US 2019/0390222 A1,137-556-177-403-051,2019-12-26,2019,US 201616071407 A,2016-12-30,US 201616071407 A;;US 201662287197 P;;US 2016/0069442 W,2016-01-26,SYSTEMS AND METHODS FOR IN VIVO DUAL RECOMBINASE-MEDIATED CASSETTE EXCHANGE (dRMCE) AND DISEASE MODELS THEREOF,"Described herein are donor vectors and systems for use in in vivo dual recombinase-mediated cassette exchange. Also described are animal models for consistent, rigorous, and facile investigation of transgene expression. Further described are methods of screening for therapeutic drugs using these animal models, and methods of treatment",CEDARS SINAI MEDICAL CENTER,BREUNIG JOSHUA;;DANIELPOUR MOISE;;KIM GI BUM,CEDARS-SINAI MEDICAL CENTER (2017-01-10),https://lens.org/137-556-177-403-051,Patent Application,yes,0,0,13,13,20,A01K67/0275;;C12N15/8509;;A01K2217/07;;A01K2227/105;;A01K2267/0331;;A01K67/0275;;C12N15/8509;;A01K2267/0331;;A01K2217/07;;A01K2227/105;;C12N2015/8527;;C12N2015/8572;;C12N2800/30;;C12N2310/20;;A01K67/0275;;A01K2217/07;;A01K2227/105;;A01K2267/0331;;A61K48/0066;;A61K49/0008;;C12N9/22;;C12N15/11;;C12N15/8509;;C12N2015/8572;;C12N2800/80;;C12N2830/50,A01K67/027;;C12N15/85;;A61K48/00;;A61K49/00;;C12N9/22;;C12N15/11,,0,0,,,,ACTIVE
17,CN,A,CN 108884472 A,105-503-754-423-694,2018-11-23,2018,CN 201680084065 A,2016-12-30,US 201662287197 P;;US 2016/0069442 W,2016-01-26,SYSTEMS AND METHODS FOR IN VIVO DUAL RECOMBINASE-MEDIATED CASSETTE EXCHANGE (dRMCE) AND DISEASE MODELS THEREOF,"Described herein are donor vectors and systems for use in in vivo dual recombinase-mediated cassette exchange. Also described are animal models for consistent, rigorous, and facile investigation of transgene expression. Further described are methods of screening for therapeutic drugs using these animal models, and methods of treatment",CEDARS SINAI MEDICAL CENTER,BREUNIG JOSHUA;;DANIELPOUR MOISE;;KIM GI BUM,,https://lens.org/105-503-754-423-694,Patent Application,no,1,2,13,13,0,A01K67/0275;;C12N15/8509;;A01K2217/07;;A01K2227/105;;A01K2267/0331;;A01K67/0275;;C12N15/8509;;A01K2267/0331;;A01K2217/07;;A01K2227/105;;C12N2015/8527;;C12N2015/8572;;C12N2800/30;;C12N2310/20;;A01K67/0275;;A01K2217/07;;A01K2227/105;;A01K2267/0331;;A61K48/0066;;A61K49/0008;;C12N9/22;;C12N15/11;;C12N15/8509;;C12N2015/8572;;C12N2800/80;;C12N2830/50,C12N15/85,,2,0,,,"BIN GUAN等: ""Establishing isogenic inducible cell lines using founder reporter lines and recombinase-mediated cassette exchange"", 《BIOTECHNIQUES》;;MARCO OSTERWALDER等: ""Dual RMCE for efficient re-engineering of mouse mutant alleles"", 《NATURE METHODS》",PENDING
18,WO,A1,WO 2017/131926 A1,185-938-572-234-125,2017-08-03,2017,US 2016/0069442 W,2016-12-30,US 201662287197 P,2016-01-26,SYSTEMS AND METHODS FOR IN VIVO DUAL RECOMBINASE-MEDIATED CASSETTE EXCHANGE (dRMCE) AND DISEASE MODELS THEREOF,"Described herein are donor vectors and systems for use in in vivo dual recombinase-mediated cassette exchange. Also described are animal models for consistent, rigorous, and facile investigation of transgene expression. Further described are methods of screening for therapeutic drugs using these animal models, and methods of treatment",CEDARS SINAI MEDICAL CENTER,BREUNIG JOSHUA;;DANIELPOUR MOISE;;KIM GI BUM,,https://lens.org/185-938-572-234-125,Patent Application,yes,1,5,13,13,20,A01K67/0275;;C12N15/8509;;A01K2217/07;;A01K2227/105;;A01K2267/0331;;A01K67/0275;;C12N15/8509;;A01K2267/0331;;A01K2217/07;;A01K2227/105;;C12N2015/8527;;C12N2015/8572;;C12N2800/30;;C12N2310/20;;A01K67/0275;;A01K2217/07;;A01K2227/105;;A01K2267/0331;;A61K48/0066;;A61K49/0008;;C12N9/22;;C12N15/11;;C12N15/8509;;C12N2015/8572;;C12N2800/80;;C12N2830/50,C12N15/85,,2,1,072-376-079-365-392,pmc2583990;;19014667;;10.1186/1755-8417-1-3,"OSTERWALDER: ""Genome-wide identification of Hand2 target regions in mouse embryos using dRMCE, a new genetic tool"", PHD THESIS, 2012, pages 37, XP055402778, Retrieved from the Internet <URL:http://edoc.unibas.ch/18985/1/phd_thesis_final_marco_osterwalder_creative_common.pdf> [retrieved on 20170305];;HOHENSTEIN ET AL.: ""High-efficiency Rosa26 knock-in vector construction for Cre-regulated overexpression and RNAi"", PATHOGENETICS, vol. 1, no. 1, 2008, pages 3, XP021045822",PENDING
19,AU,B2,AU 2016/389495 B2,020-664-207-759-32X,2023-03-30,2023,AU 2016/389495 A,2016-12-30,US 201662287197 P;;US 2016/0069442 W,2016-01-26,Systems and methods for in vivo dual recombinase-mediated cassette exchange (dRMCE) and disease models thereof,Described herein are donor vectors and systems for use in,CEDARS SINAI MEDICAL CENTER,BREUNIG JOSHUA;;DANIELPOUR MOISE;;KIM GI BUM,,https://lens.org/020-664-207-759-32X,Granted Patent,no,1,0,13,13,0,A01K67/0275;;C12N15/8509;;A01K2217/07;;A01K2227/105;;A01K2267/0331;;A01K67/0275;;C12N15/8509;;A01K2267/0331;;A01K2217/07;;A01K2227/105;;C12N2015/8527;;C12N2015/8572;;C12N2800/30;;C12N2310/20;;A01K67/0275;;A01K2217/07;;A01K2227/105;;A01K2267/0331;;A61K48/0066;;A61K49/0008;;C12N9/22;;C12N15/11;;C12N15/8509;;C12N2015/8572;;C12N2800/80;;C12N2830/50,C12N15/85,,1,0,,,"OSTERWALDER: ""Genome-wide identification of Hand2 target regions in mouse embryos using dRMCE, a new genetic tool"", PHD THESIS, 2012, pages 37, XP055402778, Retrieved from the Internet [retrieved on 20170305]",ACTIVE
20,EP,A1,EP 3408396 A1,132-535-761-242-918,2018-12-05,2018,EP 16888589 A,2016-12-30,US 201662287197 P;;US 2016/0069442 W,2016-01-26,SYSTEMS AND METHODS FOR IN VIVO DUAL RECOMBINASE-MEDIATED CASSETTE EXCHANGE (dRMCE) AND DISEASE MODELS THEREOF,,CEDARS SINAI MEDICAL CENTER,BREUNIG JOSHUA;;DANIELPOUR MOISE;;KIM GI BUM,,https://lens.org/132-535-761-242-918,Patent Application,yes,0,1,13,13,20,A01K67/0275;;C12N15/8509;;A01K2217/07;;A01K2227/105;;A01K2267/0331;;A01K67/0275;;C12N15/8509;;A01K2267/0331;;A01K2217/07;;A01K2227/105;;C12N2015/8527;;C12N2015/8572;;C12N2800/30;;C12N2310/20;;A01K67/0275;;A01K2217/07;;A01K2227/105;;A01K2267/0331;;A61K48/0066;;A61K49/0008;;C12N9/22;;C12N15/11;;C12N15/8509;;C12N2015/8572;;C12N2800/80;;C12N2830/50,C12N15/85,,0,0,,,,PENDING
21,US,B2,US 11466290 B2,027-295-022-065-851,2022-10-11,2022,US 201616071407 A,2016-12-30,US 201616071407 A;;US 201662287197 P;;US 2016/0069442 W,2016-01-26,Systems and methods for in vivo dual recombinase-mediated cassette exchange (dRMCE) and disease models thereof,"Described herein are donor vectors and systems for use in in vivo dual recombinase-mediated cassette exchange. Also described are animal models for consistent, rigorous, and facile investigation of transgene expression. Further described are methods of screening for therapeutic drugs using these animal models, and methods of treatment.",CEDARS SINAI MEDICAL CENTER,BREUNIG JOSHUA;;DANIELPOUR MOISE;;KIM GI BUM,CEDARS-SINAI MEDICAL CENTER (2017-01-10),https://lens.org/027-295-022-065-851,Granted Patent,yes,34,0,13,13,20,A01K67/0275;;C12N15/8509;;A01K2217/07;;A01K2227/105;;A01K2267/0331;;A01K67/0275;;C12N15/8509;;A01K2267/0331;;A01K2217/07;;A01K2227/105;;C12N2015/8527;;C12N2015/8572;;C12N2800/30;;C12N2310/20;;A01K67/0275;;A01K2217/07;;A01K2227/105;;A01K2267/0331;;A61K48/0066;;A61K49/0008;;C12N9/22;;C12N15/11;;C12N15/8509;;C12N2015/8572;;C12N2800/80;;C12N2830/50,C12N15/85;;A01K67/027;;A61K48/00;;A61K49/00;;C12N9/22;;C12N15/11,,25,17,074-761-000-488-140;;031-232-946-131-00X;;075-993-933-591-894;;057-479-995-832-943;;028-286-160-495-245;;072-376-079-365-392;;028-322-378-166-570;;067-472-643-247-055;;052-423-920-476-492;;191-884-677-325-345;;090-604-998-477-103;;024-508-953-102-937;;000-799-346-880-229;;042-265-338-672-267;;023-426-218-510-824;;052-814-485-116-633;;017-932-076-483-393,10.1016/j.stem.2015.06.001;;26145478;;pmc4530040;;25702640;;10.1016/j.stemcr.2015.01.013;;pmc4375828;;10.2144/000114098;;24215638;;10.1093/nar/gni045;;pmc552971;;15741177;;10.1371/journal.pgen.1000901;;20386744;;pmc2851570;;pmc2583990;;19014667;;10.1186/1755-8417-1-3;;10.1093/nar/gnf114;;pmc135837;;12409474;;22465667;;10.1016/j.devcel.2012.01.006;;pmc4486391;;pmc3576631;;10.1038/nmeth.1521;;20953177;;10.1038/protex.2010.210;;26146073;;10.1016/j.celrep.2015.06.012;;29435804;;10.1007/s11064-018-2498-7;;27444945;;pmc4957104;;10.1038/srep30130;;10.1210/me.2006-0168;;16887884;;pmc4810967;;10.4103/1673-5374.177710;;27073356;;pmc5989694;;29706501;;10.1016/j.stemcr.2018.03.024;;17668067;;10.1371/journal.pone.0000689;;pmc1925150,"Osterwalder, Marco. “Genome-wide identification of Hand2 target regions in mouse embryos using dRMCE, a new genetic tool.” (2012). (Year: 2012).;;Chen et al. “Engineering Human Stem Cell Lines with Inducible Gene Knockout using CRISPR/Cas9” Cell Stem Cell. Aug. 6, 2015;17(2):233-44. (Year: 2015).;;International Search Report and Written Opinion for PCT/US2016/069442 dated Jun. 2, 2017, 13 pages.;;Akhtar et al., A Transposon-Mediated System for Flexible Control of Transgene Expression in Stem and Progenitor-Derived Lineages, Stem Cell Reports, 2015, vol. 4, pp. 323-331.;;Zeller et al., Gene Cutting and Pasting Just Got a Whole Lot Faster, Nature Methods, 2010, vol. 7(11), p. 861.;;International Search Report and Written Opinion for PCT/US2019/022595 dated Jun. 10, 2019, 19 pages.;;Guan et al., Establishing isogenic inducible cell lines using founder reporter lines and recombinase-mediated cassette exchange, Biotechniques, 2013, vol. 55(5), pp. 233-242.;;Cobellis et al., Tagging Genes with Cassette-Exchange Sites, Nucleic Acids Research, 2005, vol. 33(4), pp. 1-7.;;Galli et al., Distinct Roles of Hand2 in Initiating Polarity and Posterior Shh Expression during the Onset of Mouse Limb Bud Development, PLoS Genetics, 2010, vol. 6(4), pp. 1-14.;;Hohenstein et al., High-Efficiency Rosa26 Knock-in Vector Construction for Cre-Regulated Overexpression and RNAi, PathoGenetics, 2008, vol. 1(1), pp. 1-10.;;Lauth et al., Stable and Efficient Cassette Exchange Under Non-Selectable Conditions by Combined Use of Two Site-Specific Recombinases, Nucleic Acids Research 2002, vol. 30(21).;;Lopez-Rios et al., GLI3 Constrains Digit Number by Controlling Both Progenitor Proliferation and BMP-Dependent Exit to Chondrogenesis, Developmental Cell, 2012, pp. 1-70.;;Osterwalder et al., Dual RMCE for Efficient Re-Engineering of Mouse Mutant Alleles, Nature Methods, 2010, pp. 1-12.;;Osterwalder et al., Next Generation Engineering of Conditional Mouse Alleles with loxP and FRT sites by Dual RMCE, Protocol Exchange, 2010, Abstract Only.;;Osterwalder et al., Genome-Wide Identification of Hand2 Target Regions in Mouse Embryos using dRMCE, A New Genetic Tool, Basel, 2012, pp. 1-203.;;Breunig et al., Platform presentation, SNO Meeting, 2013, 16 pages.;;Breunig, et al., Ets Factors Regulate Neural Stem Cell Depletion and Gliogenesis in Ras Pathway Glioma, Cell Reports, Jul. 14, 2015, 12:258-271.;;International Search Report and Written Opinion for PCT/US2020/037946 dated Sep. 16, 2020, 14 pages.;;Zhang et al., Human Neural Stem Cells with GDNF Site-Specific Integration at AAVS1 by using AAV Vectors Retained Their Stemness, Neurochem Res, 2018, vol. 43(4), pp. 930-937.;;Karimova et al., Discovery of Nigri/nox and Panto/pox site-specific recombinase systems facilities advanced genome engineering, Sci Rep, 2016, vol. 6(30130), pp. 1-13.;;De Groot et al., In vivo induction of glial cell proliferation and axonal outgrowth and myelination by brain-derived neurotrophic factor, Mol Endocrinol, 2006, vol. 20(11), pp. 2987-2998.;;Sullivan et al., Neurotrophic factor therapy for Parkinson's disease: past, present and future, Neural Regen Res, 2016, vol. 11(2), pp. 205-207.;;EP 19768063.0 European Extended Search Report dated Nov. 24, 2021, 10 pages.;;Abbasi et al., Inducible Expression of GDNF in Transplanted PSC-Derived Neural Progenitor Cells , Stem Cell Reports, 2018, vol. 10(6), pp. 1696-1704.;;Suzuki et al., GDNF Secreting Human Neural Progenitor Cells Protect Dying Motor Neurons, but Not Their Projection to Muscle, in a Rat Model of Familial ALS, PLOS ONE, 2007, vol. 2(8).",ACTIVE
22,EP,A4,EP 3408396 A4,081-632-688-526-485,2019-10-09,2019,EP 16888589 A,2016-12-30,US 201662287197 P;;US 2016/0069442 W,2016-01-26,SYSTEMS AND METHODS FOR IN VIVO DUAL RECOMBINASE-MEDIATED CASSETTE EXCHANGE (dRMCE) AND DISEASE MODELS THEREOF,,CEDARS SINAI MEDICAL CENTER,BREUNIG JOSHUA;;DANIELPOUR MOISE;;KIM GI BUM,,https://lens.org/081-632-688-526-485,Search Report,no,1,0,13,13,0,A01K67/0275;;C12N15/8509;;A01K2217/07;;A01K2227/105;;A01K2267/0331;;A01K67/0275;;C12N15/8509;;A01K2267/0331;;A01K2217/07;;A01K2227/105;;C12N2015/8527;;C12N2015/8572;;C12N2800/30;;C12N2310/20;;A01K67/0275;;A01K2217/07;;A01K2227/105;;A01K2267/0331;;A61K48/0066;;A61K49/0008;;C12N9/22;;C12N15/11;;C12N15/8509;;C12N2015/8572;;C12N2800/80;;C12N2830/50,C12N15/85,,1,1,052-423-920-476-492,pmc3576631;;10.1038/nmeth.1521;;20953177,"OSTERWALDER M ET AL: ""Dual RMCE for efficient re-engineering of mouse mutant alleles"", NATURE METHODS, NATURE PUB. GROUP, NEW YORK, vol. 7, no. 11, 1 November 2010 (2010-11-01), pages 893 - 896, XP002611952, ISSN: 1548-7091, [retrieved on 20101017], DOI: 10.1038/NMETH.1521",PENDING
23,US,A1,US 2020/0397317 A1,076-935-707-773-527,2020-12-24,2020,US 201916975203 A,2019-03-20,US 201916975203 A;;US 201862647178 P;;US 2019/0023190 W,2018-03-23,VISUALIZATION OF 4D DYNAMIC PULSATILE FLOW,"Systems and methods for monitoring pulsatile flows are disclosed. One method includes obtaining a plurality of magnetic resonance imaging (MRI) scans of a biological structure, acquired consecutively in time, each of the MRI scans acquired using a modified True FISP sequence. The method also includes assembling the plurality of scans into a video file of the biological structure and identifying pulsatile features within the video file.",CEDARS SINAI MEDICAL CENTER,DANIELPOUR MOISE;;BINESH NADER;;PRESSMAN BARRY;;MAYA MARCEL;;GONZALEZ NESTOR,CEDARS-SINAI MEDICAL CENTER (2019-03-25),https://lens.org/076-935-707-773-527,Patent Application,yes,0,0,2,2,0,A61B5/026;;A61B5/055;;G01R33/56308;;G01R33/5614;;G01R33/56325;;G01R33/4822;;A61B5/0042;;A61B5/0042;;A61B5/02007;;A61B5/02014;;A61B5/02108;;A61B5/0263;;A61B5/0285;;A61B5/055;;A61B5/4088;;A61B5/4842;;G01R33/385;;G01R33/4822;;G01R33/5614;;G01R33/56325,A61B5/026;;A61B5/00;;A61B5/02;;A61B5/021;;A61B5/0285;;A61B5/055;;G01R33/385;;G01R33/48;;G01R33/561;;G01R33/563,,0,0,,,,DISCONTINUED
24,WO,A1,WO 2019/183234 A1,173-568-999-017-428,2019-09-26,2019,US 2019/0023190 W,2019-03-20,US 201862647178 P,2018-03-23,VISUALIZATION OF 4D DYNAMIC PULSATILE FLOW,"Systems and methods for monitoring pulsatile flows are disclosed. One method includes obtaining a plurality of magnetic resonance imaging (MRI) scans of a biological structure, acquired consecutively in time, each of the MRI scans acquired using a modified True FISP sequence. The method also includes assembling the plurality of scans into a video file of the biological structure and identifying pulsatile features within the video file.",CEDARS SINAI MEDICAL CENTER,DANIELPOUR MOISE;;BINESH NADER;;PRESSMAN BARRY;;MAYA MARCEL;;GONZALEZ NESTOR,,https://lens.org/173-568-999-017-428,Patent Application,yes,4,0,2,2,0,A61B5/026;;A61B5/055;;G01R33/56308;;G01R33/5614;;G01R33/56325;;G01R33/4822;;A61B5/0042;;A61B5/0042;;A61B5/02007;;A61B5/02014;;A61B5/02108;;A61B5/0263;;A61B5/0285;;A61B5/055;;A61B5/4088;;A61B5/4842;;G01R33/385;;G01R33/4822;;G01R33/5614;;G01R33/56325,A61B5/055;;A61B5/026;;A61B5/05;;G01R33/483;;G01R33/561;;G01R33/565,,1,1,108-753-609-475-114,12835970;;10.1007/s00330-003-1846-3,"SCHMITZ ET AL.: ""Three-dimensional true FISP for high-resolution imaging of the whole brain"", EUR RADIOL, vol. 13, no. 7, 26 February 2003 (2003-02-26), pages 1577 - 1582, XP055638027, Retrieved from the Internet <URL:https://vdocuments.site/documents/three-dimensional-true-fisp-for-high-resolution-imaging-of-the-whole-brain.html> [retrieved on 20190521]",PENDING
25,EP,A1,EP 3983000 A1,171-167-458-911-961,2022-04-20,2022,EP 20827879 A,2020-06-16,US 201962862576 P;;US 2020/0037946 W,2019-06-17,SYSTEMS AND METHODS FOR IN VIVO DUAL RECOMBINASE-MEDIATED CASSETTE EXCHANGE (DRMCE) AND DISEASE MODELS THEREOF,,CEDARS SINAI MEDICAL CENTER,BREUNIG JOSHUA;;DANIELPOUR MOISE;;KIM GI BUM;;AYALA-SARMIENTO ALBERTO;;YANG AMY,,https://lens.org/171-167-458-911-961,Patent Application,yes,0,0,9,9,41,C12N15/102;;C12N2310/20;;C12N15/86;;A01K2217/052;;A01K2217/054;;A01K67/0275;;A01K2227/105;;A01K2217/206;;A01K2217/15;;A01K2267/0331;;C12N2800/30;;C12N2800/40;;C12N2750/14143;;C12N15/907;;C12N15/90;;C12N15/86;;C12N15/102;;A01K67/0275;;A61K48/00;;A61P25/28;;A61P25/16;;C12N2750/14143;;C12N2800/40;;C12N2800/30;;A01K2227/105;;A01K2217/206;;A01K2267/0331;;C12N2310/20;;A01K67/0275;;A01K2217/052;;A01K2217/054;;A01K2217/15;;A01K2217/206;;A01K2227/105;;A01K2267/0331;;C12N15/102;;C12N15/86;;C12N15/90;;C12N2750/14143;;C12N2800/30;;C12N2800/40,A61K38/18;;A61K48/00;;C12N15/09;;C12N15/90,,0,0,,,,PENDING
26,WO,A1,WO 2020/257205 A1,064-671-512-884-09X,2020-12-24,2020,US 2020/0037946 W,2020-06-16,US 201962862576 P,2019-06-17,SYSTEMS AND METHODS FOR IN VIVO DUAL RECOMBINASE-MEDIATED CASSETTE EXCHANGE (dRMCE) AND DISEASE MODELS THEREOF,"Described herein are donor vectors and systems for use in dual recombinase-mediated cassette exchange. Also described herein are animal models and human cells for consistent, rigorous, and facile investigation of transgene expression. Further described herein are methods of screening for therapeutic drugs using these animal models, and methods of treatment.",CEDARS SINAI MEDICAL CENTER;;AYALA SARMIENTO ALBERTO;;YANG AMY,AYALA-SARMIENTO ALBERTO;;YANG AMY;;BREUNIG JOSHUA;;DANIELPOUR MOISE;;KIM GI BUM,,https://lens.org/064-671-512-884-09X,Patent Application,yes,1,3,9,9,41,C12N15/102;;C12N2310/20;;C12N15/86;;A01K2217/052;;A01K2217/054;;A01K67/0275;;A01K2227/105;;A01K2217/206;;A01K2217/15;;A01K2267/0331;;C12N2800/30;;C12N2800/40;;C12N2750/14143;;C12N15/907;;C12N15/90;;C12N15/86;;C12N15/102;;A01K67/0275;;A61K48/00;;A61P25/28;;A61P25/16;;C12N2750/14143;;C12N2800/40;;C12N2800/30;;A01K2227/105;;A01K2217/206;;A01K2267/0331;;C12N2310/20;;A01K67/0275;;A01K2217/052;;A01K2217/054;;A01K2217/15;;A01K2217/206;;A01K2227/105;;A01K2267/0331;;C12N15/102;;C12N15/86;;C12N15/90;;C12N2750/14143;;C12N2800/30;;C12N2800/40,A61K38/18;;A61K48/00;;C12N15/09;;C12N15/90,,4,4,024-508-953-102-937;;000-799-346-880-229;;042-265-338-672-267;;023-426-218-510-824,29435804;;10.1007/s11064-018-2498-7;;27444945;;pmc4957104;;10.1038/srep30130;;10.1210/me.2006-0168;;16887884;;pmc4810967;;10.4103/1673-5374.177710;;27073356,"ZHANG JINJU; LIU XIAOMEI; ZHANG YUN; LUAN ZUO; YANG YINXIANG; WANG ZHAOYAN; ZHANG CHUN: ""Human Neural Stem Cells with GDNF Site-Specific Integration at AAVS1 by Using AAV Vectors Retained Their Stemness"", NEUROCHEMICAL RESEARCH, vol. 43, no. 4, 12 February 2018 (2018-02-12), pages 930 - 937, XP036474573, DOI: 10.1007/s11064-018-2498-7;;MADINA KARIMOVA, SPLITH VICTORIA, KARPINSKI JANET, PISABARRO M. TERESA, BUCHHOLZ FRANK: ""Discovery of Nigri/nox and Panto/pox site-specific recombinase systems facilitates advanced genome engineering"", SCIENTIFIC REPORTS, vol. 6, no. 30130, 1 July 2016 (2016-07-01), pages 1 - 13, XP055735295;;DE GROOT DORIEN M., COENEN ANTON J. M., VERHOFSTAD ALBERT, VAN HERP FRANÇOIS, MARTENS GERARD J. M.: ""In vivo induction of glial cell proliferation and axonal outgrowth and myelination by brain-derived neurotrophic factor"", MOLECULAR ENDOCRINOLOGY, vol. 20, no. 11, 3 August 2006 (2006-08-03) - 1 November 2006 (2006-11-01), pages 2987 - 2998, XP055775724;;A. M.SULLIVAN, G. W. O'KEEFFE: ""Neurotrophic factor therapy for Parkinson's disease: past, present and future"", NEURAL REGENERATION RESEARCH, vol. 11, no. 2, 1 February 2016 (2016-02-01), pages 205 - 207, XP055775726",PENDING
27,CA,A1,CA 3143981 A1,176-550-089-976-551,2020-12-24,2020,CA 3143981 A,2020-06-16,US 201962862576 P;;US 2020/0037946 W,2019-06-17,SYSTEMS AND METHODS FOR IN VIVO DUAL RECOMBINASE-MEDIATED CASSETTE EXCHANGE (DRMCE) AND DISEASE MODELS THEREOF,"Described herein are donor vectors and systems for use in dual recombinase-mediated cassette exchange. Also described herein are animal models and human cells for consistent, rigorous, and facile investigation of transgene expression. Further described herein are methods of screening for therapeutic drugs using these animal models, and methods of treatment.",CEDARS SINAI MEDICAL CENTER,AYALA-SARMIENTO ALBERTO;;YANG AMY;;BREUNIG JOSHUA;;DANIELPOUR MOISE;;KIM GI BUM,,https://lens.org/176-550-089-976-551,Patent Application,no,0,0,9,9,41,C12N15/102;;C12N2310/20;;C12N15/86;;A01K2217/052;;A01K2217/054;;A01K67/0275;;A01K2227/105;;A01K2217/206;;A01K2217/15;;A01K2267/0331;;C12N2800/30;;C12N2800/40;;C12N2750/14143;;C12N15/907;;C12N15/90;;C12N15/86;;C12N15/102;;A01K67/0275;;A61K48/00;;A61P25/28;;A61P25/16;;C12N2750/14143;;C12N2800/40;;C12N2800/30;;A01K2227/105;;A01K2217/206;;A01K2267/0331;;C12N2310/20;;A01K67/0275;;A01K2217/052;;A01K2217/054;;A01K2217/15;;A01K2217/206;;A01K2227/105;;A01K2267/0331;;C12N15/102;;C12N15/86;;C12N15/90;;C12N2750/14143;;C12N2800/30;;C12N2800/40,A61K38/18;;C12N15/09;;C12N15/90,,0,0,,,,PENDING
28,US,A1,US 2022/0304286 A1,152-734-256-154-770,2022-09-29,2022,US 202017617878 A,2020-06-16,US 202017617878 A;;US 201962862576 P;;US 2020/0037946 W,2019-06-17,SYSTEMS AND METHODS FOR IN VIVO DUAL RECOMBINASE-MEDIATED CASSETTE EXCHANGE (dRMCE) AND DISEASE MODELS THEREOF,"Described herein are donor vectors and systems for use in dual recombinase-mediated cassette exchange. Also described herein are animal models and human cells for consistent, rigorous, and facile investigation of transgene expression. Further described herein are methods of screening for therapeutic drugs using these animal models, and methods of treatment.",CEDARS SINAI MEDICAL CENTER,BREUNIG JOSHUA;;DANIELPOUR MOISE;;KIM GI BUM;;AYALA-SARMIENTO ALBERTO;;YANG AMY,CEDARS-SINAI MEDICAL CENTER (2020-06-18),https://lens.org/152-734-256-154-770,Patent Application,yes,0,0,9,9,41,C12N15/102;;C12N2310/20;;C12N15/86;;A01K2217/052;;A01K2217/054;;A01K67/0275;;A01K2227/105;;A01K2217/206;;A01K2217/15;;A01K2267/0331;;C12N2800/30;;C12N2800/40;;C12N2750/14143;;C12N15/907;;C12N15/90;;C12N15/86;;C12N15/102;;A01K67/0275;;A61K48/00;;A61P25/28;;A61P25/16;;C12N2750/14143;;C12N2800/40;;C12N2800/30;;A01K2227/105;;A01K2217/206;;A01K2267/0331;;C12N2310/20;;A01K67/0275;;A01K2217/052;;A01K2217/054;;A01K2217/15;;A01K2217/206;;A01K2227/105;;A01K2267/0331;;C12N15/102;;C12N15/86;;C12N15/90;;C12N2750/14143;;C12N2800/30;;C12N2800/40,A01K67/027;;C12N15/10;;C12N15/86;;C12N15/90,,0,0,,,,PENDING
29,AU,A1,AU 2020/297427 A1,098-398-931-685-887,2022-02-03,2022,AU 2020/297427 A,2020-06-16,US 201962862576 P;;US 2020/0037946 W,2019-06-17,Systems and methods for in vivo dual recombinase-mediated cassette exchange (dRMCE) and disease models thereof,"Described herein are donor vectors and systems for use in dual recombinase-mediated cassette exchange. Also described herein are animal models and human cells for consistent, rigorous, and facile investigation of transgene expression. Further described herein are methods of screening for therapeutic drugs using these animal models, and methods of treatment.",CEDARS SINAI MEDICAL CENTER,BREUNIG JOSHUA;;DANIELPOUR MOISE;;KIM GI BUM;;AYALA-SARMIENTO ALBERTO;;YANG AMY,,https://lens.org/098-398-931-685-887,Patent Application,no,0,0,9,9,0,C12N15/102;;C12N2310/20;;C12N15/86;;A01K2217/052;;A01K2217/054;;A01K67/0275;;A01K2227/105;;A01K2217/206;;A01K2217/15;;A01K2267/0331;;C12N2800/30;;C12N2800/40;;C12N2750/14143;;C12N15/907;;C12N15/90;;C12N15/86;;C12N15/102;;A01K67/0275;;A61K48/00;;A61P25/28;;A61P25/16;;C12N2750/14143;;C12N2800/40;;C12N2800/30;;A01K2227/105;;A01K2217/206;;A01K2267/0331;;C12N2310/20;;A01K67/0275;;A01K2217/052;;A01K2217/054;;A01K2217/15;;A01K2217/206;;A01K2227/105;;A01K2267/0331;;C12N15/102;;C12N15/86;;C12N15/90;;C12N2750/14143;;C12N2800/30;;C12N2800/40,A61K38/18;;A61K48/00;;C12N15/09;;C12N15/90,,0,0,,,,PENDING
30,EP,A4,EP 3983000 A4,172-421-756-700-107,2023-10-11,2023,EP 20827879 A,2020-06-16,US 201962862576 P;;US 2020/0037946 W,2019-06-17,SYSTEMS AND METHODS FOR IN VIVO DUAL RECOMBINASE-MEDIATED CASSETTE EXCHANGE (DRMCE) AND DISEASE MODELS THEREOF,,CEDARS SINAI MEDICAL CENTER,BREUNIG JOSHUA;;DANIELPOUR MOISE;;KIM GI BUM;;AYALA-SARMIENTO ALBERTO;;YANG AMY,,https://lens.org/172-421-756-700-107,Search Report,no,1,0,9,9,0,C12N15/102;;C12N2310/20;;C12N15/86;;A01K2217/052;;A01K2217/054;;A01K67/0275;;A01K2227/105;;A01K2217/206;;A01K2217/15;;A01K2267/0331;;C12N2800/30;;C12N2800/40;;C12N2750/14143;;C12N15/907;;C12N15/90;;C12N15/86;;C12N15/102;;A01K67/0275;;A61K48/00;;A61P25/28;;A61P25/16;;C12N2750/14143;;C12N2800/40;;C12N2800/30;;A01K2227/105;;A01K2217/206;;A01K2267/0331;;C12N2310/20;;A01K67/0275;;A01K2217/052;;A01K2217/054;;A01K2217/15;;A01K2217/206;;A01K2227/105;;A01K2267/0331;;C12N15/102;;C12N15/86;;C12N15/90;;C12N2750/14143;;C12N2800/30;;C12N2800/40,A61K38/18;;A61K48/00;;C12N15/09;;C12N15/90,,10,9,091-066-638-574-63X;;052-423-920-476-492;;027-146-657-219-94X;;016-080-832-933-553;;062-481-341-561-025;;097-676-167-574-217;;010-366-854-343-947;;034-803-431-720-134;;059-401-144-530-536,10.1093/nar/gks027;;22270085;;pmc3333864;;pmc3576631;;10.1038/nmeth.1521;;20953177;;30024101;;10.1002/biot.201800226;;pmc7058118;;10.1093/neuonc/noz036.258;;10.1021/acs.chemrev.6b00077;;27163859;;23201421;;10.1016/j.gene.2012.11.016;;26455413;;pmc4649136;;10.1016/j.stemcr.2015.09.004;;17868096;;10.1002/dvg.20335;;10.1111/febs.13345;;26077105;;pmc4558331,"ANDERSON RACHELLE P. ET AL: ""Flp and Cre expressed from Flp-2A-Cre and Flp-IRES-Cre transcription units mediate the highest level of dual recombinase-mediated cassette exchange"", NUCLEIC ACIDS RESEARCH, vol. 40, no. 8, 1 April 2012 (2012-04-01), GB, pages e62 - e62, XP093047833, ISSN: 0305-1048, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3333864/pdf/gks027.pdf> DOI: 10.1093/nar/gks027;;OSTERWALDER M ET AL: ""Dual RMCE for efficient re-engineering of mouse mutant alleles"", NATURE METHODS, NATURE PUBLISHING GROUP US, NEW YORK, vol. 7, no. 11, 1 November 2010 (2010-11-01), pages 893 - 896, XP002611952, ISSN: 1548-7091, [retrieved on 20101017], DOI: 10.1038/NMETH.1521;;SOFIE A O'BRIEN ET AL: ""Single Copy Transgene Integration in a Transcriptionally Active Site for Recombinant Protein Synthesis"", BIOTECHNOLOGY JOURNAL, WILEY-VCH VERLAG, WEINHEIM, DE, vol. 13, no. 10, 30 July 2018 (2018-07-30), pages n/a, XP072415582, ISSN: 1860-6768, DOI: 10.1002/BIOT.201800226;;OSTERWALDER: ""Genome-wide identification of Hand2 target regions in mouse embryos using dRMCE, a new genetic tool"", PHD THESIS, 1 January 2012 (2012-01-01), pages 1 - 306, XP055402778, Retrieved from the Internet <URL:http://edoc.unibas.ch/18985/1/phd_thesis_final_marco_osterwalder_creative_common.pdf> [retrieved on 20170831];;GRAUSAM KATIE B ET AL: ""EXPANDING A PEDIATRIC GLIOMA TOOLKIT OF GENETIC MANIPULATION TO GENERATE TERTIARY MODES OF INDUCIBLE RECOMBINASE EXPRESSION"", NEURO-ONCOLOGY, 1 April 2019 (2019-04-01), pages AA125 - AA125, XP093048339, Retrieved from the Internet <URL:https://watermark.silverchair.com/noz036.258.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAwgwggMEBgkqhkiG9w0BBwagggL1MIIC8QIBADCCAuoGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMB3mD3NBbPH-RAQ4WAgEQgIICu4z5jvzQyCHgpm0rNkuMXsJ9JtGpMxRhKf1568yfcA0xF7I6RaP0MXrJ8AUeROGeMZ3sQ6r4Cjcwd9mmWeigYK3I9> [retrieved on 20230522], DOI: 10.1093/neuonc/noz036.258;;GRETCHEN MEINKE ET AL: ""Cre Recombinase and Other Tyrosine Recombinases"", CHEMICAL REVIEWS, vol. 116, no. 20, 10 May 2016 (2016-05-10), US, pages 12785 - 12820, XP055620771, ISSN: 0009-2665, DOI: 10.1021/acs.chemrev.6b00077;;SOEREN TURAN ET AL: ""Recombinase-mediated cassette exchange (RMCE) — A rapidly-expanding toolbox for targeted genomic modifications"", GENE, vol. 515, no. 1, 1 February 2013 (2013-02-01), NL, pages 1 - 27, XP055383251, ISSN: 0378-1119, DOI: 10.1016/j.gene.2012.11.016;;ORDOVÁS LAURA ET AL: ""Efficient Recombinase-Mediated Cassette Exchange in hPSCs to Study the Hepatocyte Lineage Reveals AAVS1 Locus-Mediated Transgene Inhibition"", STEM CELL REPORTS, vol. 5, no. 5, 10 November 2015 (2015-11-10), pages 918 - 931, XP093016645;;MANDAR DEEPAK MUZUMDAR ET AL: ""A global double-fluorescent Cre reporter mouse"", GENESIS, WILEY-LISS, HOBOKEN, USA, vol. 45, no. 9, 14 September 2007 (2007-09-14), pages 593 - 605, XP072305348, ISSN: 1526-954X, DOI: 10.1002/DVG.20335;;RIDDHI SHAH ET AL: ""Target-specific variants of Flp recombinase mediate genome engineering reactions in mammalian cells"", THE FEBS JOURNAL, vol. 282, no. 17, 1 July 2015 (2015-07-01), GB, pages 3323 - 3333, XP055507827, ISSN: 1742-464X, DOI: 10.1111/febs.13345",PENDING
31,US,A1,US 2019/0237189 A1,163-102-769-147-756,2019-08-01,2019,US 201916367559 A,2019-03-28,US 201916367559 A;;US 2017/0056676 W;;US 201662410390 P,2016-10-20,"PERIOPERATIVE WORKFLOW SYSTEM, ARCHITECTURE, AND INTERFACE THERETO","A system supporting perioperative workflow includes a backend system with at least one database; at least one application configured with the database(s); and at least one user interface (UI) mechanism supporting a plurality of role-specific graphical user interfaces (GUIs) to the backend system. The backend system maintains an authoritative version of perioperative workflow information for each of a plurality of patients. One or more devices are configured with at least some of the role-specific GUIs, and operably connected to and interact with the backend system via the UI mechanism(s). Each device is configured to: receive and display perioperative workflow information from the backend system in a role-specific GUI on the device; and to send perioperative workflow information to the backend system via the role-specific GUI on the device.",LOGICAL MEDICAL SYSTEMS INC,GELLER DAVID;;PANKAU EDWIN;;ARANGO PADGETT;;CLARK ANDRE;;NAKABAYASHI DEAN;;DANIELPOUR MOISE;;SHATTUCK CHRISTOPHER,LOGICAL MEDICAL SYSTEMS INC (2016-10-20),https://lens.org/163-102-769-147-756,Patent Application,yes,0,32,5,5,0,G16H40/67;;G16H40/20;;G06Q10/0633;;G16H40/67;;G16H40/20;;G06F3/0482;;G06Q10/0633,G16H40/20;;G06F3/0482;;G06Q10/06,,0,0,,,,DISCONTINUED
32,CA,A1,CA 3038990 A1,124-269-487-860-369,2018-04-26,2018,CA 3038990 A,2017-10-13,US 201662410390 P;;US 2017/0056676 W,2016-10-20,"PERIOPERATIVE WORKFLOW SYSTEM, ARCHITECTURE, AND INTERFACE THERETO","A system supporting perioperative workflow includes a backend system with at least one database; at least one application configured with the database(s); and at least one user interface (UI) mechanism supporting a plurality of role-specific graphical user interfaces (GUIs) to the backend system. The backend system maintains an authoritative version of perioperative workflow information for each of a plurality of patients. One or more devices are configured with at least some of the role-specific GUIs, and operably connected to and interact with the backend system via the UI mechanism(s). Each device is configured to: receive and display perioperative workflow information from the backend system in a role-specific GUI on the device; and to send perioperative workflow information to the backend system via the role-specific GUI on the device.",LOGICAL MEDICAL SYSTEMS INC,GELLER DAVID;;PANKAU EDWIN;;ARANGO PADGETT;;CLARK ANDRE;;NAKABAYASHI DEAN;;DANIELPOUR MOISE;;SHATTUCK CHRISTOPHER,,https://lens.org/124-269-487-860-369,Patent Application,no,0,0,5,5,0,G16H40/67;;G16H40/20;;G06Q10/0633;;G16H40/67;;G16H40/20;;G06F3/0482;;G06Q10/0633,G06F3/048,,0,0,,,,DISCONTINUED
33,WO,A1,WO 2018/075370 A1,032-122-580-580-271,2018-04-26,2018,US 2017/0056676 W,2017-10-13,US 201662410390 P,2016-10-20,"PERIOPERATIVE WORKFLOW SYSTEM, ARCHITECTURE, AND INTERFACE THERETO","A system supporting perioperative workflow includes a backend system with at least one database; at least one application configured with the database(s); and at least one user interface (UI) mechanism supporting a plurality of role-specific graphical user interfaces (GUIs) to the backend system. The backend system maintains an authoritative version of perioperative workflow information for each of a plurality of patients. One or more devices are configured with at least some of the role-specific GUIs, and operably connected to and interact with the backend system via the UI mechanism(s). Each device is configured to: receive and display perioperative workflow information from the backend system in a role-specific GUI on the device; and to send perioperative workflow information to the backend system via the role-specific GUI on the device.",LOGICAL MEDICAL SYSTEMS INC,GELLER DAVID;;PANKAU EDWIN;;ARANGO PADGETT;;CLARK ANDRE;;NAKABAYASHI DEAN;;DANIELPOUR MOISE;;SHATTUCK CHRISTOPHER,,https://lens.org/032-122-580-580-271,Patent Application,yes,3,0,5,5,0,G16H40/67;;G16H40/20;;G06Q10/0633;;G16H40/67;;G16H40/20;;G06F3/0482;;G06Q10/0633,G06F3/048,,1,0,,,See also references of EP 3529688A4,PENDING
34,EP,A1,EP 3529688 A1,058-618-022-914-110,2019-08-28,2019,EP 17862056 A,2017-10-13,US 201662410390 P;;US 2017/0056676 W,2016-10-20,"PERIOPERATIVE WORKFLOW SYSTEM, ARCHITECTURE, AND INTERFACE THERETO",,LOGICAL MEDICAL SYSTEMS INC,GELLER DAVID;;PANKAU EDWIN;;ARANGO PADGETT;;CLARK ANDRE;;NAKABAYASHI DEAN;;DANIELPOUR MOISE;;SHATTUCK CHRISTOPHER,,https://lens.org/058-618-022-914-110,Patent Application,yes,0,0,5,5,0,G16H40/67;;G16H40/20;;G06Q10/0633;;G16H40/67;;G16H40/20;;G06F3/0482;;G06Q10/0633,G06F3/048,,0,0,,,,DISCONTINUED
35,EP,A4,EP 3529688 A4,198-577-781-365-990,2020-06-03,2020,EP 17862056 A,2017-10-13,US 201662410390 P;;US 2017/0056676 W,2016-10-20,"PERIOPERATIVE WORKFLOW SYSTEM, ARCHITECTURE, AND INTERFACE THERETO",,LOGICAL MEDICAL SYSTEMS INC,GELLER DAVID;;PANKAU EDWIN;;ARANGO PADGETT;;CLARK ANDRE;;NAKABAYASHI DEAN;;DANIELPOUR MOISE;;SHATTUCK CHRISTOPHER,,https://lens.org/198-577-781-365-990,Search Report,no,2,0,5,5,0,G16H40/67;;G16H40/20;;G06Q10/0633;;G16H40/67;;G16H40/20;;G06F3/0482;;G06Q10/0633,G16H40/00;;G06F3/048,,1,0,,,See also references of WO 2018075370A1,DISCONTINUED
